Ovarian cancer as a genetic disease.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2741/4119PMID 23276941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of soluble interleukin-6 receptor in malignant ovarian tissue.

  2010cited by this paper
• Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer

  2010cited by this paper
• Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells

  2010cited by this paper
• p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.

  2010cited by this paper
• VEGF-Targeted Short Hairpin RNA Inhibits Intraperitoneal Ovarian Cancer Growth in Nude Mice

  2010cited by this paper
• A Small Molecule Inhibits Akt through Direct Binding to Akt and Preventing Akt Membrane Translocation*

  2010cited by this paper
• Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.

  2010cited by this paper
• The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.

  2010cited by this paper
• Low membranous expression of β-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary

  2010cited by this paper
• Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer

  2010cited by this paper
• Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary

  2010cited by this paper
• Limited prognostic value of tissue protein expression levels of BCl‐2 in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study

  2010cited by this paper
• The Complex Relationship between BRCA1 and ERα in Hereditary Breast Cancer

  2009cited by this paper
• Influence of Race/Ethnicity on Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer

  2009cited by this paper
• PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients

  2009cited by this paper
• Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation

  2009cited by this paper
• KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

  2009cited by this paper
• Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

  2009cited by this paper
• PIK3CA alterations in Middle Eastern ovarian cancers

  2009cited by this paper
• The biology of ovarian cancer: new opportunities for translation

  2009cited by this paper
• RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo

  2009cited by this paper
• Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

  2009cited by this paper
• Aberrant promoter methylation of SPARC in ovarian cancer.

  2009cited by this paper
• Electronic Health Records and the Management of Women at High Risk of Hereditary Breast and Ovarian Cancer

  2009cited by this paper
• BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

  2009cited by this paper
• Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation

  2009cited by this paper
• Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.

  2009cited by this paper
• MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent

  2008cited by this paper
• Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

  2008cited by this paper
• Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice

  2008cited by this paper
• MDM2SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk

  2008cited by this paper
• Targeting phosphoinositide 3-kinase: moving towards therapy.

  2008cited by this paper
• Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.

  2008cited by this paper
• Association of Genetic Variation in Genes Implicated in the β-Catenin Destruction Complex with Risk of Breast Cancer

  2008cited by this paper
• Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer

  2008cited by this paper
• Tissue AP-2γ and Oct-3/4, and Serum CA 125 as Diagnostic and Prognostic Markers of Malignant Ovarian Germ Cell Tumors

  2008cited by this paper
• SPARC ameliorates ovarian cancer-associated inflammation.

  2008cited by this paper
• Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.

  2007cited by this paper
• Expression of Brcal is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice

  2007cited by this paper
• The folate receptor: What does it promise in tissue-targeted therapeutics?

  2007cited by this paper
• Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

  2007cited by this paper
• Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer.

  2007cited by this paper
• Bevacizumab in the treatment of ovarian cancer

  2007cited by this paper
• SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.

  2007cited by this paper
• Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer

  2007cited by this paper
• Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

  2007cited by this paper
• Ovarian cancer hormonal and environmental risk effect.

  2007cited by this paper
• Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.

  2007cited by this paper
• The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma.

  2006cited by this paper
• Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

  2006cited by this paper
• The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer.

  2006cited by this paper
• Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins.

  2006cited by this paper
• A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.

  2006cited by this paper
• Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2α

  2006cited by this paper
• Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer

  2006cited by this paper
• High frequency of β‐catenin mutations in borderline endometrioid tumours of the ovary

  2006cited by this paper
• Interleukin-6: a new therapeutic target

  2006cited by this paper
• KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.

  2006cited by this paper
• The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander?

  2006cited by this paper
• HER-2/neu and bcl-2 in Ovarian Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival

  2006cited by this paper
• The role of BRCA1 in transcriptional regulation and cell cycle control

  2006cited by this paper
• Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma.

  2006cited by this paper
• Origins and molecular pathology of ovarian cancer

  2005cited by this paper
• Advances in the understanding of risk factors for ovarian cancer.

  2005cited by this paper
• Biochip for K-ras mutation screening in ovarian cancer.

  2005cited by this paper
• Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis

  2005cited by this paper
• Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition.

  2005cited by this paper
• Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up

  2005cited by this paper
• The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin.

  2005cited by this paper
• Therapeutic potential of inhibitory VEGF splice variants.

  2005cited by this paper
• The KRAS oncogene: past, present, and future.

  2005cited by this paper
• Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

  2005cited by this paper
• Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes

  2005cited by this paper
• Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells

  2005cited by this paper
• Contraction-Induced Myokine Production and Release: Is Skeletal Muscle an Endocrine Organ?

  2005cited by this paper
• Biological Relevance of E-Cadherin-Catenin Complex Proteins in Primary Epithelial Ovarian Tumours

  2005cited by this paper
• Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.

  2005cited by this paper
• Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.

  2005cited by this paper
• PIK3CA mutations in advanced ovarian carcinomas

  2005cited by this paper
• Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination.

  2005cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma

  2004cited by this paper
• Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2α

  2004cited by this paper
• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer.

  2004cited by this paper
• Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer

  2004cited by this paper
• A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

  2004cited by this paper
• Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

  2004cited by this paper
• Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients.

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Loss of beta-catenin is associated with poor survival in ovarian carcinomas.

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.

  2004cited by this paper
• Nuclear β‐catenin in basal cell carcinoma correlates with increased proliferation

  2004cited by this paper
• p27/Kip1 mediates retinoic acid‐induced suppression of ovarian carcinoma cell growth

  2004cited by this paper
• Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.

  2003influential reference
• The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

  2003cited by this paper
• Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

  2003cited by this paper
• P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens.

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper

• Constructing gene similarity networks using co-occurrence probabilities

  2023cites this paper
• LeMeDISCO is a computational method for large-scale prediction & molecular interpretation of disease comorbidity

  2022cites this paper
• Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile

  2020cites this paper
• Identification of core genes in ovarian cancer by an integrative meta-analysis

  2018cites this paper
• Advanced in Zheng Research in Digestive System Malignant Tumor

  2017cites this paper
• Stress-Adaptive Response in Ovarian Cancer Drug Resistance: Role of TRAP1 in Oxidative Metabolism-Driven Inflammation.

  2017cites this paper
• Advanced in Zheng Research in Digestive System Malignant Tumor

  2017cites this paper
• Research advances in traditional Chinese medicine syndromes in cancer patients.

  2016cites this paper
• Nicotinamide adenine dinucleotide (NAD) may affect DNA methyltransferase 1 through regulation of BRCA1 in ovarian cancer.

  2015cites this paper
• BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer

  2014cites this paper
• BRCA1 regulates insulin-like growth factor 1 receptor levels in ovarian cancer

  2014cites this paper
• A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer

  2014cites this paper
• The development of intratumoral heterogeneity in ovarian tumors: role of cancer stem cells in disease progression

  2014influential citation
• MicroRNAs and Clinical Implications in Cancer

  2014cites this paper
• Preparation and characterization of luteinising-hormone releasing hormone nanoliposomal microbubbles specifically targeting ovarian cancer cells in vitro.

  2014cites this paper
• Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses.

  2014cites this paper
• Poly (ADP-ribose) polymerase 1 transcriptional regulation: A novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer

  2013cites this paper